KL-6 levels in COVID-19

Scarpati, Giuliana; Polverino, Benedetto; Boffardi, Massimo; Piazza, Ornella

doi:10.37825/2239-9747.1014

Cited by 2 publications

(2 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 study was found by manually searching ( Zeng et al, 2020 ).Of these, 1 meeting abstract, 2 not written in the English language, 40 not relevant, 2 reviews were excluded. The full text of 33 remained studies was assessed for eligibility and 12 case reports or case series ( Horii et al, 2020 ; Inoue et al, 2020 ; Ito et al, 2020 ; Nakamura et al, 2020 ; Scarpati, 2020 , Shibata et al, 2020 ; Shimazu et al, 2020 ; Zeng et al, 2020a ; Fukada et al, 2021 ; Sumimoto et al, 2021 ; Suzuki et al, 2021 ; Yamaya et al, 2021 ), 2 studies that did not report the results clearly ( Miyagami et al, 2021 ; Takeshita et al, 2021 ), 3 studies that did not classify patients based on disease severity ( Frix et al, 2020 ; Chen et al, 2021a ; Scotto et al, 2021 ) and 1 preprint study ( Alimova et al, 2020 ) were excluded. Finally, 15 studies identified as relevant and entered the quality assessment ( Awano et al, 2020 , d'Alessandro et al, 2020a , d'Alessandro and Cameli, 2020 , d'Alessandro et al, 2020b ; Frix et al, 2020 ; jp, 2020 , Saito et al, 2020 ; Wang et al, 2020 ; Xue et al, 2020 ; Anai et al, 2021 ; Bergantini et al, 2021 ; Chen et al, 2021 , d’Alessandro et al, 2021 ; Deng et al, 2021 ; He et al, 2021 ; Peng et al, 2021 ; Scotto et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses

Naderi

Rahimzadeh

2022

Virology

View full text Add to dashboard Cite

Background Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells, and has been proposed as a marker of COVID-19 and the severity of the disease. Here, we performed a meta-analysis to determine whether KL-6 could be used as a prognostic factor for severe COVID-19. Methods PubMed, Cochrane and Google Scholar were searched until April 20, 2021, and 7 studies were included. KL-6 was considered as the outcome and pooled in meta-analyses. Results All included studies compared KL-6 in severe and non-severe patients. Serum KL-6 was higher in severe COVID-19 patients compared to non-severe (n = 6; SMD = 1.25; 95% CI: 0.99–1.5; P < 0.001) and healthy controls (n = 4; SMD = 3.07; 95% CI: 1.36–4.8; P < 0.001). Conclusion This data collection revealed the potential clinical significance of KL-6 as a non-expensive predictive biomarker in severe COVID-19 and for the categorization of COVID-19 clinical severity.

show abstract

Section: Resultsmentioning

confidence: 99%

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses

Naderi

Rahimzadeh

2022

Virology

View full text Add to dashboard Cite

show abstract

“…KL-6 is a novel biomarker for ILD, and it is produced by injured/regenerating type II pneumocytes as well as bronchial epithelial cells and other cells [ 7 , 18 , 19 ]. Recent studies have explored the association between KL-6 levels and COVID-19 disease severity or prognosis; KL-6 levels increased according to COVID-19 disease severity and significantly predicted hospital days and poor prognosis in some studies [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. KL-6 has been also suggested as a potential biomarker for post-COVID-19 PF [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Usefulness of KL-6 for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients

et al. 2022

View full text Add to dashboard Cite

Background: Krebs von den Lungen 6 (KL-6) is a novel biomarker for interstitial lung disease, and it reflects acute lung injury. We explored the usefulness of KL-6 to predict clinical outcomes in hospitalized coronavirus disease 2019 (COVID-19) patients. Methods: In a total of 48 hospitalized COVID-19 patients, KL-6 levels were measured using the HISCL KL-6 assay (Sysmex, Kobe, Japan) with the HISCL 5000 automated analyzer (Sysmex). Clinical outcomes (intensive care unit [ICU] admission, ventilator use, extracorporeal membrane oxygenation [ECMO] use, and 30-day mortality) were analyzed according to KL-6 percentiles. Age, initial KL-6 level, Charlson comorbidity index (CCI), and critical disease were compared using the receiver operating characteristic (ROC) curve and Kaplan–Meier methods for clinical outcomes. Results: KL-6 quartiles were associated with ICU admission, ventilator use, and ECMO use (all p < 0.05), except 30-day mortality (p = 0.187). On ROC curve analysis, initial KL-6 level predicted ICU admission, ventilator use, and ECMO use significantly better than age, CCI, and critical disease (all p < 0.05); age, initial KL-6 level, CCI, and critical disease predicted 30-day mortality comparably. On Kaplan–Meier survival analysis, hazard ratios (95% confidence interval) were 4.8 (1.2–19.3) for age, 4.7 (1.1–21.6) for initial KL-6 level, 3.9 (0.9–16.2) for CCI, and 2.1 (0.5–10.3) for critical disease. Conclusions: This study demonstrated that KL-6 could be a useful biomarker to predict clinical outcomes in hospitalized COVID-19 patients. KL-6 may contribute to identifying COVID-19 patients requiring critical care, including ICU admission and ventilator and/or ECMO use.

show abstract

KL-6 levels in COVID-19

Cited by 2 publications

References 3 publications

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses

Usefulness of KL-6 for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients

Contact Info

Product

Resources

About